The effect of tumor size and metastatic extent on the efficacy of first line pembrolizumab monotherapy in patients with high PD-L1 expressing advanced NSCLC tumors

Lung cancer is one of the most common cancer types and is the leading cause of cancer-related deaths [1]. In metastatic stage NSCLC, the introduction of immune checkpoint inhibitors (ICI) revolutionized the treatment landscape. Currently, pembrolizumab monotherapy is the standard of care in NSCLC patients with high tumor PD-L1 expression (PD-L1 ≥50%) [4]. However, despite promising results, not all patients benefit from ICI therapy. This highlights not only the need for better therapies, but also the need for insight in selecting the right therapy for the right patients based on strong predictive biomarkers.

Source: Lung Cancer - October 11, 2021 Category: Cancer & Oncology Authors: Alexandra Schakenraad, Sayed Hashemi, Jos Twisk, Ilias Houda, Ezgi Ulas, Johannes M.A. Daniels, Joris Veltman, I. Bahce Source Type: research